AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership
July 17, 2023 07:00 ET
|
AccuStem Sciences, Inc
LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and...
AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
July 11, 2023 07:00 ET
|
AccuStem Sciences, Inc
StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrence LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE)...
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
April 28, 2022 08:40 ET
|
AccuStem Sciences, Inc
LONDON and PHOENIX, April 28, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its...
AccuStem Sciences, Inc. Announces DTC Eligibility
April 14, 2022 07:00 ET
|
AccuStem Sciences, Inc
LONDON and PHOENIX, April 14, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to announce...
AccuStem Announces Private Placement of Common Stock
April 05, 2022 12:32 ET
|
AccuStem Sciences, Inc
LONDON and PHOENIX, April 05, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that it...
AccuStem Sciences, Inc. Announces DTC Eligibility
March 23, 2022 07:36 ET
|
AccuStem Sciences, Inc
LONDON and PHOENIX, March 23, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to...
AccuStem Sciences, Inc. Appoints New Executive Leadership Team
March 04, 2022 07:00 ET
|
AccuStem Sciences, Inc
LONDON and PHOENIX, March 04, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC PINK: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, today announced the...
AccuStem’s StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort
March 01, 2022 07:00 ET
|
Accustem Sciences, Inc
LONDON and PHOENIX, March 01, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC PINK: ACMSY), a life sciences company dedicated to improving outcomes for patients with cancer, today announced...
ACCUSTEM SCIENCES LIMITED (‘ACCUSTEM UK’) and ACCUSTEM SCIENCES INC (‘ACCUSTEM US’): Recommended corporate reorganisation by means of a Scheme of Arrangement under Part 26 of the Companies Act 2006
December 01, 2021 08:10 ET
|
Accustem Sciences Limited
SCHEME OF ARRANGEMENT EFFECTIVE LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- ACCUSTEM UK is pleased to announce that, further to the announcement dated 30 November 2021 that the Court has sanctioned...
ACCUSTEM SCIENCES LIMITED (‘ACCUSTEM UK’) and ACCUSTEM SCIENCES INC (‘ACCUSTEM US’) Recommended corporate reorganisation by means of a Scheme of Arrangement under Part 26 of the Companies Act 2006
November 30, 2021 12:41 ET
|
Accustem Sciences Limited
LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Reference is made to the terms of a recommended corporate reorganisation be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of...